Max Cure’s Dedication to Restarting Childhood Cancer Research
From the beginning of the current global health pandemic caused by COVID-19, the Max Cure Foundation grew concerned about the impact to come on the childhood cancer community. From the
Permanent Reauthorization of the Creating Hope Act
It began in September 2011 when Max Plotkin, then 8 years old and a 4-year cancer survivor addressed an audience of over 500 people, including members of Congress, scientists, industryDonate $5 in December
Take Part in Max Cure’s BIGGEST Social Fundraiser Ever Attempted! This year, The Max Cure Foundation is setting our most ambitious social fundraising goal to date! We started with the
Crunch-Time Champions Still Giving Thrills
CLEVELAND, Feb. 26, 2019 /PRNewswire/ — Cleveland Crunch players are coming together for another championship effort to celebrate the 25th anniversary of giving fans in Northeastern Ohio a coveted pro sports championship. Partnering with two
Dad challenges D.C. United goalie to help families battling childhood cancer
WASHINGTON (ABC7) — While playoff-bound D.C. United practiced Wednesday, 47-year-old Jonathan Agin warmed up on a nearby field for a unique showdown with one of the team’s goalkeepers, Travis Worra. Agin,
In Loss of Young Son to Cancer, Dad Gets Ink & Makes a Change
An Army staff sergeant is changing his life to honor his 9-year-old son who died recently of cancer. And he got a tattoo to raise awareness and money for cancerSean Marriott | Roar Beyond Barriers
Sean Marriott is 7-years-old and the youngest of 3 children of Kelly Marriott and her ex-husband, Chris. Sean, with his brothers, was enjoying the summer on a family vacation atThe Max Cure Foundation’s Commitment to Collaboration
Executive Director Jonathan Agin recently traveled to Seattle, Washington from June 12-14th to attend the annual meeting of the Coalition Against Childhood Cancer, also known as CAC2. CAC2 began toRACE for Children Act | Pediatric Oncology Subcommittee
Executive Director Jonathan Agin Provides Public Comment Before the Food and Drug Administration On June 20, 2018, Executive Director Jonathan Agin provided open public comments before the Food and Drug